Denovicon Therapeutics is currently focused on small-molecule therapeutics for a variety of targets in the DNA damage response (DDR) pathways and immuno-oncology. In particular, we are progressing first-in-class molecules that selectively target PARP1 and PARP2 for various diseases in oncology, immunology, neuroscience, and cardiovascular, as well as PARP7 for multiple oncology indications.